Citadel Advisors
NVLN

Citadel Advisors’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Citadel Advisors’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-119,560
Closed -$87K – 10222
2019
Q3 		$87K Buy
119,560
+27,723
+30% +$20.1K ﹤0.01% 8546
2019
Q2 		$72K Buy
91,837
+31,150
+51% +$34.7K ﹤0.01% 8630
2019
Q1 		$75K Buy
+60,687
New +$69.1K ﹤0.01% 8658
2018
Q1 		– Sell
-19,655
Closed -$61K – 9074
2017
Q4 		$61K Buy
+19,655
New +$94.5K ﹤0.01% 7572

Other funds holding NVLN

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return

Citadel Advisors's NVLN Position: Q4 2019 in Review

Citadel Advisors sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2019, closing a stake of 119,560 shares — an estimated $87K sold.

Citadel Advisors first reported a position in NVLN in Q4 2017 and held it in 4 quarters. The position peaked at $87K in Q3 2019. 7 funds tracked by Wall St. Rank hold NVLN as of Q4 2019.

  • Citadel Advisors reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2019 after selling out during the quarter.
  • Citadel Advisors sold 119,560 Novelion Therapeutics Inc. Common Shares shares in Q4 2019, an estimated $87K.
  • Citadel Advisors first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2017 and held it in 4 quarters.
  • Citadel Advisors's Novelion Therapeutics Inc. Common Shares position peaked at $87K in Q3 2019.
  • 7 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2019.

Based on Citadel Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.